Search Results - "Alagappan, Vijay"

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study by KERWIN, Edward, HEBERT, Jacques, GALLAGHER, Nicola, MARTIN, Carmen, OVEREND, Tim, ALAGAPPAN, Vijay K. T, LU, Yimeng, BANERJI, Donald

“…NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The…”
Get full text

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study by MAHLER, Donald A, DECRAMER, Marc, D'URZO, Anthony, WORTH, Heinrich, WHITE, Tracy, ALAGAPPAN, Vijay K. T, HUNGTA CHEN, GALLAGHER, Nicola, KULICH, Károly, BANERJI, Donald

“…We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported dyspnoea in patients with…”
Get full text

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study by Vogelmeier, Claus F, Prof, Bateman, Eric D, Prof, Pallante, John, BS, Alagappan, Vijay KT, MD, D'Andrea, Peter, MD, Chen, Hungta, PhD, Banerji, Donald, MD

“…Summary Background QVA149 is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive pulmonary disease (COPD). It…”
Get full text

Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study by Dahl, Ronald, Chapman, Kenneth R, Rudolf, Michael, Mehta, Rajendra, Kho, Pearl, Alagappan, Vijay K.T, Chen, Hungta, Banerji, Donald

“…Summary Background QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of the long-acting β2 -agonist indacaterol and long-acting…”
Get full text

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Erratum in: Int J Chron Obstruct Pulmon Dis. 2014;9:85 Note: MEDLINE/PubMed abstract corrected; Dosage error in article text.] by Dahl, Ronald, Jadayel, Dalal, Alagappan, Vijay K T, Chen, Hungta, Banerji, Donald

“…The BEACON study evaluated the efficacy and safety of QVA149, a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting…”
Get full text

Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials by Martinez, Fernando J, Rabe, Klaus F, Calverley, Peter M A, Fabbri, Leonardo M, Sethi, Sanjay, Pizzichini, Emilio, McIvor, Andrew, Anzueto, Antonio, Alagappan, Vijay K T, Siddiqui, Shahid, Reisner, Colin, Zetterstrand, Sofia, Román, Jonas, Purkayastha, Debasree, Bagul, Nitin, Rennard, Stephen I

“…Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of…”
Get full text

Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study by O'Byrne, Paul M, FitzGerald, J Mark, Bateman, Eric D, Barnes, Peter J, Zheng, Jinping, Gustafson, Per, Lamarca, Rosa, Puu, Margareta, Keen, Christina, Alagappan, Vijay K T, Reddel, Helen K

“…In mild asthma, as-needed budesonide–formoterol reduces long-term exacerbation risk compared with as-needed short-acting β2-agonist (SABA), with a similar or…”
Get full text

Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma by Reddel, Helen K., O’Byrne, Paul M., FitzGerald, J. Mark, Barnes, Peter J., Zheng, Jinping, Ivanov, Stefan, Lamarca, Rosa, Puu, Margareta, Alagappan, Vijay K.T., Bateman, Eric D.

“…Medication adherence is challenging for adolescents. In mild asthma, as-needed budesonide-formoterol (BUD-FORM) reduces severe exacerbations compared with…”
Get full text

Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial by Rabe, Klaus F, Watz, Henrik, Baraldo, Simonetta, Pedersen, Frauke, Biondini, Davide, Bagul, Nitin, Hanauer, Guido, Göhring, Udo-Michael, Purkayastha, Debasree, Román, Jonas, Alagappan, Vijay K T, Saetta, Marina

“…The clinical effects of roflumilast, a selective phosphodiesterase-4 inhibitor, are well established, but little is known about the anti-inflammatory…”
Get full text

Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies by FitzGerald, J. Mark, O’Byrne, Paul M., Bateman, Eric D., Barnes, Peter J., Zheng, Jinping, Ivanov, Stefan, Lamarca, Rosa, Larsdotter, Ulrika, Emerath, Ulrika, Jansen, Gerreke, Puu, Margareta, Alagappan, Vijay K. T., Surmont, Filip, Reddel, Helen K.

“…Introduction Budesonide-formoterol taken as needed is an emerging treatment for mild asthma. Objective We used data from the SYGMA studies to assess the safety…”
Get full text

96-Channel receive-only head coil for 3 Tesla: Design optimization and evaluation by Wiggins, Graham C., Polimeni, Jonathan R., Potthast, Andreas, Schmitt, Melanie, Alagappan, Vijay, Wald, Lawrence L.

“…The benefits and challenges of highly parallel array coils for head imaging were investigated through the development of a 3T receive‐only phased‐array head…”
Get full text

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD by Watz, Henrik, Bagul, Nitin, Rabe, Klaus F, Rennard, Stephen, Alagappan, Vijay Kt, Román, Jonas, Facius, Axel, Calverley, Peter Ma

“…The oral selective phosphodiesterase-4 inhibitor roflumilast (ROF) reduces exacerbations in patients with severe COPD. Adverse events (AEs) can cause early ROF…”
Get full text

Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease by KRANENBURG, Andor R, WILLEMS-WIDYASTUTI, Anna, MOOI, Wolter J, STERK, Peter J, ALAGAPPAN, Vijay K. T, DE BOER, Willem I, SHARMA, Hari S

“…Remodeling of airways and blood vessels is an important feature in chronic obstructive pulmonary disease (COPD). By using immunohistochemical analysis, we…”
Get full text

Angiogenesis and Vascular Remodeling in Chronic Airway Diseases by Alagappan, Vijay K. T., de Boer, Willem I., Misra, Virendra K., Mooi, Wolter J., Sharma, Hari S.

“…Asthma and chronic obstructive pulmonary disease remain a global health problem, with increasing morbidity and mortality. Despite differences in the causal…”
Get full text

Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function" by Reddel, Helen K, O'Byrne, Paul M, FitzGerald, J Mark, Barnes, Peter J, Zheng, Jinping, Ivanov, Stefan, Lamarca, Rosa, Puu, Margareta, Alagappan, Vijay K T, Bateman, Eric D

“…To the Editor: We thank Shanthikumar and Robinson for their comments about our paper on as-needed budesonide-formoterol compared with as-needed short-acting…”
Get full text

Role of extracellular matrix and its regulators in human airway smooth muscle biology by Parameswaran, Krishnan, Willems-Widyastuti, Anna, Alagappan, Vijay K T, Radford, Katherine, Kranenburg, Andor R, Sharma, Hari S

“…Altered extracellular matrix (ECM) deposition contributing to airway wall remodeling is an important feature of asthma and chronic obstructive pulmonary…”
Get full text

Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart by Das, Samarjit, Alagappan, Vijay K T, Bagchi, Debasis, Sharma, Hari S, Maulik, Nilanjana, Das, Dipak K

“…Existing evidence indicates that resveratrol, a red wine and grape-derived polyphenolic antioxidant, can pharmacologically precondition the heart in a nitric…”
Get full text

Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy by de Boer, Willem I, Alagappan, Vijay K T, Sharma, Hari S

“…Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease associated with progressive airflow obstruction. Tobacco smoking is the…”
Get full text

A novel model-based approach for dose determination of glycopyrronium bromide in COPD by Arievich, Helen, Overend, Tim, Renard, Didier, Gibbs, Michael, Alagappan, Vijay, Looby, Michael, Banerji, Donald

“…Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and…”
Get full text

Nitric Oxide Donors Augment Interleukin-1β-Induced Vascular Endothelial Growth Factor in Airway Smooth Muscle Cells by Sharma, Hari S., Alagappan, Vijay K. T., Willems-Widyastuti, Anna, Mooi, Wolter J., de Boer, Willem I.

“…Angiogenesis and microvascular leakage are features of chronic inflammatory diseases of which molecular mechanisms are poorly understood. We investigated the…”
Get full text